PROMIS Profile-29是测量慢性肝病患者生活质量的有效工具,与旧版工具相比具有明显优势
研究纳入204例慢性肝病门诊患者,比较PROMIS Profile-29与SF-36、CLDQ的生活质量测量性能。Profile-29完成更快(5.4±3.0分钟 vs SF-36 6.7±3.3分钟 vs CLDQ 6.5±5.2分钟,p=0.003),可用性相当,且无地板/天花板效应,而SF-36和CLDQ所有维度均出现地板或天花板效应。
要点
- Profile-29与SF-36或CLDQ测量相似概念的维度间呈强相关(r≥0.7),聚合效度强。
- 合并肝硬化或并发症与多数Profile-29维度评分更差相关,已知组效度良好。
- Profile-29完成时间短于SF-36和CLDQ(p=0.003),可用性评分与二者相当。
核心结论
- Profile-29是有效、更高效且接受度好的工具,与SF-36和CLDQ相比提供更好的测量深度,因此是测量慢性肝病总体健康相关生活质量的理想工具。
研究设计与样本
- 研究纳入204例慢性肝病成年门诊患者,完成PROMIS-29、CLDQ、SF-36及可用性问卷。
- 比较组间平均评分,评估维度评分间相关性,并计算地板/天花板效应。
主要发现
- 慢性肝病病因构成为非酒精性脂肪性肝病(44%)、丙型肝炎(16%)和酒精(16%)。
- 53%患者有肝硬化,33%为Child-Pugh B/C级,平均终末期肝病模型评分为12.0。
- 三种工具中评分最差的维度均为躯体功能和疲劳。
- 合并肝硬化或并发症与多数PROMIS Profile-29维度评分更差相关,表明已知组效度。
- Profile-29与SF-36或CLDQ测量相似概念的维度间呈强相关(r≥0.7),表明聚合效度强。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The Patient-Reported Outcomes Measurement Information System (PROMIS) is increasingly used to measure health-related quality of life, yet, it has not been well-studied in chronic liver disease (CLD). This study compares PROMIS Profile-29 to Short-Form Health Survey (SF-36) and Chronic Liver Disease Questionnaire (CLDQ) in patients with CLD. APPROACH AND RESULTS: In all, 204 adult outpatients with CLD completed PROMIS-29, CLDQ, SF-36 and usability questionnaires. Mean scores were compared between groups, the correlation between domain scores was assessed, and floor/ceiling effects were calculated. Etiologies of CLD were NAFLD (44%), hepatitis C (16%), and alcohol (16%). Fifty-three percent had cirrhosis and 33% were Child-Pugh B/C with a mean model for end-stage liver disease score of 12.0. In all 3 tools, the poorest scores were in physical function and fatigue. The presence of cirrhosis or complications was associated with worse scores in most PROMIS Profile-29 domains, indicating known group validity. Strong correlations ( r ≥ 0.7) were present between Profile-29 and SF-36 or CLDQ domains measuring similar concepts, indicating strong convergent validity. Profile-29 was completed faster than SF-36 and CLDQ (5.4 ± 3.0, 6.7 ± 3.3, 6.5 ± 5.2 min, p = 0.003) and rated equally on usability. All CLDQ and SF-36 domains reached the floor or ceiling, while none were noted for Profile-29. These floor/ceiling effects were magnified when assessed in those with and without cirrhosis, indicating the improved depth of measurement by Profile-29. CONCLUSIONS: Profile-29 is a valid, more efficient, well-received tool that provides an improved depth of measurement when compared to SF-36 and CLDQ and, therefore, an ideal tool to measure general health-related quality of life in CLD.
引用
- Desai AP, Madathanapalli A, Tang Q, et al. PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease. Hepatology. 2023. PMID: 37222262. doi:10.1097/HEP.0000000000000480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。